AZD 2858

Key Product Details

Product Description

AZD 2858 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor (IC₅₀ values are 0.9 and 5 nM for GSK-3α and GSK-3β, respectively). AZD 2858 inhibits tau phosphorylation in vitro (IC₅₀ = 76 nM), improves fracture healing and increases bone mass in rodent models of bone fracture. Also activates Wnt signaling in vitro and in vivo. Brain permeable and orally bioavailable.

Product Specifications for AZD 2858

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for AZD 2858

The following data is based on the product molecular weight 453.52.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	22.05 mL	110.25 mL	220.50 mL
0.5 mM	4.41 mL	22.05 mL	44.10 mL
1 mM	2.20 mL	11.02 mL	22.05 mL
5 mM	0.44 mL	2.20 mL	4.41 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Berg Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J.Med.Chem. 2012 PMID: 22489897
• Cook Wnt-dependent osteogenic commitment of bone marrow stromal cells using a novel GSK3β inhibitor. Stem Cell Res. 2014 PMID: 24382458
• Sisask Rats treated with AZD2858, a GSK3 inhibitor, heal fractures rapidly without endochondral bone formation. Bone 2013 PMID: 23337038

Product Documents for AZD 2858